With GLP-1 receptor agonists, the ADA-EASD consensus states that SGLT2 inhibitors are preferably considered in T2D patients with established ASCVD, heart failure, or CKD, and patients who need to minimize weight-related and excessive hypoglycemic problems (if the estimated glomerular filtration rate (eGFR) is adequate) [10]. Here, SLC5A2 is linked to type 2 diabetes mellitus.